Prostate Cancer Clinical Trial

Docetaxel in Treating Patients With Stage II or Stage III Prostate Cancer

Summary

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.

PURPOSE: Phase II trial to study the effectiveness of docetaxel in treating patients who have stage II or stage III prostate cancer.

View Full Description

Full Description

OBJECTIVES: I. Determine the pathologic complete response rate to docetaxel in patients with high risk stage II or III prostate cancer. II. Determine the toxicity of this treatment in these patients. III. Correlate clinical measures of response (e.g., symptoms, physical exam, serum PSA, and endorectal MRI) with pathologic response to this treatment in these patients.

OUTLINE: Patients receive docetaxel IV over 30 minutes weekly for 4 weeks. Treatment continues for 2-6 courses in the absence of disease progression or unacceptable toxicity.

PROJECTED ACCRUAL: A total of 19-45 patients will be accrued for this study over 18 months.

View Eligibility Criteria

Eligibility Criteria

Eligibility Criteria:

Histologically confirmed adenocarcinoma of the prostate
Potential candidate for radical prostatectomy

Any of the following:

Clinical stage T3 patients
Serum PSA at least 20 ng/mL
Gleason score 8-10

Clinical T2 disease and either of the following:

MRI evidence of seminal vesicle involvement
Gleason 4+3 cancer with either 5 or 6 biopsies positive
CALGB 0-1
WBC greater than 3,000/mm3
Hematocrit greater than 30%
Platelet count greater than 100,000/mm3
SGOT, total bilirubin within normal limits
Signed Informed consent

Exclusion Criteria:

No prior hormones, radiation or chemotherapy for prostate cancer
Evidence of serious active infection

Study is for people with:

Prostate Cancer

Phase:

Phase 2

Estimated Enrollment:

19

Study ID:

NCT00005096

Recruitment Status:

Completed

Sponsor:

Dana-Farber Cancer Institute

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 2 Locations for this study

See Locations Near You

Massachusetts General Hospital
Boston Massachusetts, 02114, United States
Beth Israel Deaconess Medical Center
Boston Massachusetts, 02115, United States
Dana-Farber Cancer Institute
Boston Massachusetts, 02115, United States

How clear is this clinincal trial information?

Study is for people with:

Prostate Cancer

Phase:

Phase 2

Estimated Enrollment:

19

Study ID:

NCT00005096

Recruitment Status:

Completed

Sponsor:


Dana-Farber Cancer Institute

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider